SEC Info - Edwards Lifesciences Corp.

SEC Info℠

Home

Help

Please Sign In

Edwards Lifesciences Corp. – ‘8-K’ for 4/20/21

On: Tuesday, 4/20/21, at 4:26pm ET · For: 4/20/21 · Accession #: 1099800-21-10 · File #: 1-15525

  As Of               Filer                 Filing    For·On·As Docs:Size

 4/20/21  Edwards Lifesciences Corp.        8-K:2,9     4/20/21   13:1.3M

Current Report — Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     29K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    134K 
 9: R1          Cover Page                                          HTML     46K 
11: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- ew-20210420_htm                     XML     22K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.CAL  XBRL Calculations -- ew-20210420_cal                 XML      7K 
 5: EX-101.DEF  XBRL Definitions -- ew-20210420_def                  XML      9K 
 6: EX-101.LAB  XBRL Labels -- ew-20210420_lab                       XML     68K 
 7: EX-101.PRE  XBRL Presentations -- ew-20210420_pre                XML     33K 
 3: EX-101.SCH  XBRL Schema -- ew-20210420                           XSD     11K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    17K 
13: ZIP         XBRL Zipped Folder -- 0001099800-21-000010-xbrl      Zip     29K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

ew-20210420

i 0001099800 i false00010998002021-04-202021-04-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) i April 20, 2021

i EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

i Delaware

i 1-15525

i 36-4316614

(State or other jurisdiction
of incorporation)

(Commission
file number)

(IRS Employer
Identification No.)

i One Edwards Way

i Irvine, i California i 92614

(Address of principal executive offices and zip code)

( i 949) i 250-2500

(Registrant's telephone number, including area code)


N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


i ☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, par value $1.00 per share	i EW	i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On April 20, 2021, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the first quarter of 2021. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference.

The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.

Item 9.01. Financial Statements and Exhibits.


			(d)			Exhibits

			99.1			Press release, dated April 20, 2021, reporting Edwards’ financial results for the first quarter of 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: i April 20, 2021

	EDWARDS LIFESCIENCES CORPORATION

	By:	/s/ *Scott B. Ullem*
		Scott B. Ullem
		Chief Financial Officer

Exhibit Index


Exhibit Number						Description
99.1						Press release, dated April 20, 2021, reporting Edwards’ financial results for the first quarter of 2021.

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	4/20/21	None on these Dates
		List all Filings

↑Top

Filing Submission 0001099800-21-000010 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)